82 related articles for article (PubMed ID: 23987046)
1. [The evaluation of efficacy and safety of treatment with dalfaz SR in patients with prostatic adenoma].
Rasner PI; Pushkar' DIu
Urologiia; 2013; (3):34-6, 38. PubMed ID: 23987046
[TBL] [Abstract][Full Text] [Related]
2. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
4. Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
Saad F; Nickel JC; Valiquette L; Casey R; Kuzmarov I; Elhilali M;
Can J Urol; 2005 Aug; 12(4):2745-54. PubMed ID: 16197598
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Sánchez-Chapado M; Guil M; Alfaro V; Badiella L; Fernández-Hernando N
Eur Urol; 2000 Apr; 37(4):421-7. PubMed ID: 10765072
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of prostatic adenoma treatment with alfusozine depending on sexuality].
Kogan MI; Kireev AIu
Urologiia; 2011; (1):28-31. PubMed ID: 21500491
[TBL] [Abstract][Full Text] [Related]
8. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
9. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
10. [Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
Serment G; Rossi D; Reitz C; Boumendil O
Prog Urol; 2000 Apr; 10(2):254-60. PubMed ID: 10857143
[TBL] [Abstract][Full Text] [Related]
11. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and urodynamic evaluation of efficacy of conservative treatment of urination disorders in patients with benign prostate hyperplasia].
Danilov VV; Danilova TI; Danilov VV; Danilov VV
Urologiia; 2013; (5):55-8. PubMed ID: 24437242
[TBL] [Abstract][Full Text] [Related]
13. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Tsuritani S; Nozaki T; Okumura A; Kimura H; Kazama T
Urol Int; 2010; 85(1):80-7. PubMed ID: 20516676
[TBL] [Abstract][Full Text] [Related]
16. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Fourcade RO
Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
[TBL] [Abstract][Full Text] [Related]
17. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
18. The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Sánchez-Chapado M; Guil M; Badiella LI; Fernández-Hernando N; Alfaro V
BJU Int; 2000 Sep; 86(4):432-8. PubMed ID: 10971267
[TBL] [Abstract][Full Text] [Related]
19. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
[TBL] [Abstract][Full Text] [Related]
20. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
Loran OB; Pushkar' DIu; Rasner PI
Urologiia; 2000; (2):3-5. PubMed ID: 11186726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
